Jasper Therapeutics Reports Preliminary Data From Ongoing SPOTLIGHT Phase 1b/2a Study Of Subcutaneous Briquilimab; Says 14 Of 15 Participants Enrolled Achieved Clinical Response
Jasper Therapeutics Reports Preliminary Data From Ongoing SPOTLIGHT Phase 1b/2a Study Of Subcutaneous Briquilimab; Says 14 Of 15 Participants Enrolled Achieved Clinical Response
Jasper expects to present full data from the SPOTLIGHT study in the first half of 2025.14 of 15 participants (93%) enrolled in both dose cohorts of the study (n=15) achieved a clinical response within the 6-week preliminary analysis period following administration.
在研究的兩個劑量組（n=15）中，有14名參與者（93%）在6周的初步分析期內取得臨床反應。
In the 120mg dose cohort, 10 of 12 participants (83%) experienced a complete response (CR), and 1 participant experienced a partial response (PR). Briquilimab was well tolerated in the study, with no serious adverse events (SAEs) and no grade 3 or higher adverse events (AEs) reported.
在120mg劑量組中，12名參與者中有10名（83%）達到了完全反應（CR），1名參與者達到了局部反應（PR）。Briquilimab在研究中耐受良好，沒有發生嚴重不良事件（SAEs），也沒有報告3級或更高級別的不良事件（AEs）。
In alignment with the Company's clinical development plan, Jasper has obtained regulatory clearance to enroll a 180mg dose cohort (n=12) in the SPOTLIGHT study.
與公司的臨床開發計劃一致，Jasper已獲得監管許可，將在SPOTLIGHt研究中招募180mg劑量組（n=12）。
Jasper expects to present full data from the SPOTLIGHT study in the first half of 2025.
Jasper預計將在2025年上半年公佈SPOTLIGHt研究的完整數據。
Jasper also announced that it expects to report initial data from all cohorts of the BEACON study in CSU during the week of January 6th, 2025, including the recently added 180mg Q8W dose cohort.
Jasper還宣佈預計將於2025年1月6日當週報告CSU BEACON研究的所有劑量組的初步數據，包括最近加入的180mg Q8W劑量組。
譯文內容由第三人軟體翻譯。
